HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

9.460

+0.0600.64%

Volume:2.18M

Turnover:20.38M

Market Cap:3.85B

PE:-10.66

High:9.490

Open:9.445

Low:9.255

Close:9.400

52wk High:679.500

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.56

T/O Rate:0.70%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.888

ROE:-36.78%

ROA:-20.32%

PB:3.75

PE(LYR):-10.66

PS:92.98

Loading ...

Overview Company News Filings

TransThera Sciences Posts Steady August 2026 Share Capital; Confirms Public Float Compliance

Bulletin Express

TransThera Sciences (Nanjing) (SEHK:2617) Stock Sees Revenue Emerge As Losses Persist

Simply Wall St.

TransThera Sciences turns first-half revenue positive on licensing deal, narrows loss to RMB95.47 million

Bulletin Express

Transthera Sciences’ Tinengotinib Wins Conditional China NMPA Approval for Cholangiocarcinoma

Transthera Sciences FY26 H1 Net Loss Narrows to RMB 95.47 Million; Revenue Rises to RMB 35.46 Million

TRANSTHERA-B: Ching Fen Chan Tan Disposes of Shares, Long Position Falls to 5.76%

TRANSTHERA-B: Ghalibo (PTC) Limited Disposes of Shares, Long Position Falls to 5.76%

TRANSTHERA-B: Morningside Venture (I) Investments Limited Disposes of Shares, Long Position Falls to 5.76%

TRANSTHERA-B: Morningside Bio-Ventures Limited Disposes of Shares, Long Position Falls to 5.76%

TransThera Sciences Schedules 26 August Board Meeting to Review 1H 2026 Results and Consider Interim Dividend

Bulletin Express

TransThera Sciences Schedules Board Meeting to Review Interim Results

TRANSTHERA-B: Future Industry Investment Fund II (Limited Partnership) Disposes of Shares, Long Position Falls to 5.85%

China NMPA Approves TransThera’s Yochanra for FGFR Inhibitor-Resistant Cholangiocarcinoma

TRANSTHERA-B Shares Jump Over 12% in Morning Trading After Core Drug Tenagotinib Gets Market Approval

TransThera Wins China Marketing Approval for Bile Duct Cancer Drug

MT Newswires Live

Movement Alert｜TRANSTHERA-B Rises 21.51% in Regular Trading, Core Drug Tinengotinib Receives NMPA Conditional Approval

Transthera-B secures NMPA approval for Je'ente in advanced bile duct cancer treatment

Transthera Sciences (Nanjing) - Nmpa Grants Marketing Approval for Yochanra (Tinengotinib Tablets)

THOMSON REUTERS

Genecare Development Reduces Stake in TRANSTHERA-B, Sells 467,500 Shares at Approximately HK$12.58 Each

TRANSTHERA-B: Morningside Venture (I) Investments Limited Sees Disposal of Shares, Long Position Falls to 6.87%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/02617/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":9.46,"timestamp":1789027724004,"preClose":9.4,"halted":0,"volume":2176000,"delay":0,"changeRate":0.006382978723404308,"floatShares":312000000,"shares":407000000,"eps":-0.887653968602481,"marketStatus":"Not Yet Opened","change":0.06,"latestTime":"09-10 16:08:44","open":9.445,"high":9.49,"low":9.255,"amount":20379607,"amplitude":0.025,"askPrice":9.46,"askSize":5000,"bidPrice":9.455,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":-0.7855433951037435,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":9.4,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.563016,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-20.32%","roe":"-36.78%","lyrEps":-0.887654,"volumeRatio":0.563016,"shares":407000000,"dividePrice":0,"high":9.49,"amplitude":0.025,"preClose":9.4,"low":9.255,"week52Low":9.01,"pbRate":"3.75","psRate":"92.98","week52High":679.5,"institutionHeld":0,"latestPrice":9.46,"committee":0.6,"eps":-0.887653968602481,"divideRate":0,"volume":2176000,"delay":0,"ttmEps":-0.7855433951037435,"open":9.445,"prevYearClose":114.9,"prevWeekClose":10.15,"prevMonthClose":10.17,"prevQuarterClose":11.55,"fiveDayClose":10.09,"twentyDayClose":10.66,"sixtyDayClose":29.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-09-09","current":-12.028245,"percent":0.94,"low":-380.446233,"twenty":-196.609225,"median":-71.813981,"eighty":-33.547213,"high":-10.87103,"avg":-110.355125,"sd":96.342477,"marketCap":3834435150},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106},{"date":"2026-08-28","current":-13.544101,"twenty":-206.454369,"median":-79.928564,"eighty":-37.623415,"marketCap":4242353783},{"date":"2026-09-04","current":-13.213217,"twenty":-200.748681,"median":-72.756691,"eighty":-35.040401,"marketCap":4140374124},{"date":"2026-09-09","current":-12.217317,"twenty":-196.609225,"median":-71.813981,"eighty":-33.547213,"marketCap":3834435150}],"updateTime":1789034520933},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1115766616","title":"TransThera Sciences Posts Steady August 2026 Share Capital; Confirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1115766616","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115766616?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:23","pubTimestamp":1788348190,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has released its Monthly Return for Equity Issuer for the period ended 31 August 2026, showing no changes in either authorised or issued share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662308477","title":"TransThera Sciences (Nanjing) (SEHK:2617) Stock Sees Revenue Emerge As Losses Persist","url":"https://stock-news.laohu8.com/highlight/detail?id=2662308477","media":"Simply Wall St.","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662308477?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:35","pubTimestamp":1787834115,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) stock came into this earnings print bruised, with the 90 day return deep in the red despite a small bounce over the past week and month. Yet the latest H1 2026 numbers tell a more nuanced story. Revenue landed at C¥35.455 million, a clear shift for a company that previously reported no sales, while earnings still showed a sizeable loss with basic earnings per share of C¥0.24 in the red. The real question for the market now is whether this early top line traction...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2617/transthera-sciences-nanjing-shares/news/transthera-sciences-nanjing-sehk2617-stock-sees-revenue-emer","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2617/transthera-sciences-nanjing-shares/news/transthera-sciences-nanjing-sehk2617-stock-sees-revenue-emer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165891458","title":"TransThera Sciences turns first-half revenue positive on licensing deal, narrows loss to RMB95.47 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1165891458","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165891458?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:42","pubTimestamp":1787740943,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. reported its first meaningful revenue and a sharply reduced interim loss for the six months ended 30 June 2026, driven by an upfront payment from a licensing...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"TransThera Sciences turns first-half revenue positive on licensing deal, narrows loss to RMB95.47 million","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797038","title":"Transthera Sciences’ Tinengotinib Wins Conditional China NMPA Approval for Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797038","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797038?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:24","pubTimestamp":1787739876,"startTime":"0","endTime":"0","summary":"Transthera Sciences’ tinengotinib wins conditional China NMPA approval for cholangiocarcinomaTransthera Sciences’ tinengotinib won conditional NMPA approval on Aug. 6, 2026 for FGFR2 fusion/rearrangem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL2YKGVJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662977247","title":"Transthera Sciences FY26 H1 Net Loss Narrows to RMB 95.47 Million; Revenue Rises to RMB 35.46 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662977247","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662977247?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:23","pubTimestamp":1787739806,"startTime":"0","endTime":"0","summary":"Transthera Sciences FY26 H1 net loss narrows to RMB 95.47 million; revenue rises to RMB 35.46 millionTransthera Sciences posted a net loss of RMB 95.47 million, narrowing from RMB 122.87 million a yea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL2bv27N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127962724","title":"TRANSTHERA-B: Ching Fen Chan Tan Disposes of Shares, Long Position Falls to 5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127962724","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127962724?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:16","pubTimestamp":1787649417,"startTime":"0","endTime":"0","summary":"On August 20, 2026, Ching Fen Chan Tan sold 1.00 million shares of TRANSTHERA-B (H shares) at an average of HKD 10.5891 per share, involving about HKD 10.59 million.Prior to the disposal, Ching Fen...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138671629","title":"TRANSTHERA-B: Ghalibo (PTC) Limited Disposes of Shares, Long Position Falls to 5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138671629","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138671629?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:14","pubTimestamp":1787649247,"startTime":"0","endTime":"0","summary":"On August 20, 2026, Ghalibo (PTC) Limited sold 1.00 million shares of TRANSTHERA-B (02617) at an average of HKD 10.59 per share, involving about HKD 10.59 million.Prior to the disposal, Ghalibo (PTC)...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100275431","title":"TRANSTHERA-B: Morningside Venture (I) Investments Limited Disposes of Shares, Long Position Falls to 5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100275431","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100275431?lang=en_us&edition=fundamental","pubTime":"2026-08-24 17:18","pubTimestamp":1787563091,"startTime":"0","endTime":"0","summary":"Morningside Venture (I) Investments Limited sold 1.00 million shares of TRANSTHERA-B at an average of HKD 10.5891 per share on August 20, 2026, involving about HKD 10.59 million.Prior to the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117316614","title":"TRANSTHERA-B: Morningside Bio-Ventures Limited Disposes of Shares, Long Position Falls to 5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117316614","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117316614?lang=en_us&edition=fundamental","pubTime":"2026-08-24 17:17","pubTimestamp":1787563036,"startTime":"0","endTime":"0","summary":"On August 20, 2026, Morningside Bio-Ventures Limited sold 1.00 million shares of TRANSTHERA-B (02617) stock at an average of HKD 10.5891 per share, involving about HKD 10.59 million.Prior to the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131549459","title":"TransThera Sciences Schedules 26 August Board Meeting to Review 1H 2026 Results and Consider Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1131549459","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131549459?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:27","pubTimestamp":1786699647,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. has notified shareholders that its board of directors will convene on 26 August 2026 in Hong Kong. The meeting’s agenda includes three primary items: 1. Review and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659114041","title":"TransThera Sciences Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659114041","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659114041?lang=en_us&edition=fundamental","pubTime":"2026-08-14 16:58","pubTimestamp":1786697918,"startTime":"0","endTime":"0","summary":"TransThera Sciences schedules board meeting to review interim resultsTransThera Sciences (Nanjing) schedules a board meeting for Aug. 26, 2026 to review interim results for the six months ended June 3","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL7R5pD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120497991","title":"TRANSTHERA-B: Future Industry Investment Fund II (Limited Partnership) Disposes of Shares, Long Position Falls to 5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120497991","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120497991?lang=en_us&edition=fundamental","pubTime":"2026-08-10 17:11","pubTimestamp":1786353113,"startTime":"0","endTime":"0","summary":"Future Industry Investment Fund II (Limited Partnership) sold 1.77 million shares of TRANSTHERA-B stock at an average of HKD 13.74 per share on August 7, 2026, involving about HKD 24.36 million.Prior...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657973826","title":"China NMPA Approves TransThera’s Yochanra for FGFR Inhibitor-Resistant Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657973826","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657973826?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:45","pubTimestamp":1786085149,"startTime":"0","endTime":"0","summary":"China NMPA approves TransThera’s Yochanra for FGFR inhibitor-resistant cholangiocarcinomaChina’s NMPA cleared TransThera’s Yochanra for FGFR2 fusion- or rearrangement-positive advanced cholangiocarcin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL93NWZp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174583245","title":"TRANSTHERA-B Shares Jump Over 12% in Morning Trading After Core Drug Tenagotinib Gets Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1174583245","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174583245?lang=en_us&edition=fundamental","pubTime":"2026-08-07 09:50","pubTimestamp":1786067457,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) opened more than 28% higher in early trading, later trimming gains to trade up 12.06% at HK$12.92, with turnover reaching HK$226 million.The company announced last night that its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IPOS","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657608016","title":"TransThera Wins China Marketing Approval for Bile Duct Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2657608016","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657608016?lang=en_us&edition=fundamental","pubTime":"2026-08-07 09:38","pubTimestamp":1786066710,"startTime":"0","endTime":"0","summary":"TransThera Sciences   said China's National Medical Products Administration granted conditional marketing approval for Yochanra  to treat adults with unresectable advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement.The approval covers patients who have received prior systemic therapy and FGFR inhibitor treatment, according to a Thursday Hong Kong bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134394496","title":"Movement Alert｜TRANSTHERA-B Rises 21.51% in Regular Trading, Core Drug Tinengotinib Receives NMPA Conditional Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1134394496","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134394496?lang=en_us&edition=fundamental","pubTime":"2026-08-07 09:31","pubTimestamp":1786066277,"startTime":"0","endTime":"0","summary":"On August 7, TRANSTHERA-B rose 21.51% in regular trading, trading at HKD 13.98/share, with turnover of HKD 62.53 million.On the news front, the company announced on August 6 that its independently...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144029631","title":"Transthera-B secures NMPA approval for Je'ente in advanced bile duct cancer treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1144029631","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144029631?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:10","pubTimestamp":1786018220,"startTime":"0","endTime":"0","summary":"Transthera-B (02617) has announced that its independently developed Class 1 new drug, Je'ente® (Tinengotinib Tablets), has received conditional marketing approval from the National Medical Products...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636408","title":"Transthera Sciences (Nanjing) - Nmpa Grants Marketing Approval for Yochanra (Tinengotinib Tablets)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636408?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:04","pubTimestamp":1786017851,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4431H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123232974","title":"Genecare Development Reduces Stake in TRANSTHERA-B, Sells 467,500 Shares at Approximately HK$12.58 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1123232974","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123232974?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:32","pubTimestamp":1786015954,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on August 5, Genecare Development Limited reduced its holdings in TRANSTHERA-B (02617) by 467,500 shares, with a transaction price of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106321119","title":"TRANSTHERA-B: Morningside Venture (I) Investments Limited Sees Disposal of Shares, Long Position Falls to 6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106321119","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106321119?lang=en_us&edition=fundamental","pubTime":"2026-08-06 17:15","pubTimestamp":1786007706,"startTime":"0","endTime":"0","summary":"On August 5, 2026, Morningside Venture (I) Investments Limited sold 467,500 shares of TRANSTHERA-B (02617) at an average of HKD 12.5786 per share, involving about HKD 5.88 million.Prior to the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":147,"code":"91000000","status":"200"}]}}